NovoPro
Cart 2
  • Anti-c-Met/HGFR antibody

Anti-c-Met/HGFR antibody

Cat.#: 102623

Special Price 145.0 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    Anti-c-Met/HGFR antibody
  • Documents
  • Description
    Mouse monoclonal to c-Met/HGFR
  • Tested applications
    ELISA
  • Species reactivity
    Human c-MET / HGFR
    No cross-reactivity with Human cell lysate (293 cell line) in WB and ELISA.
  • Alternative names
    hCG_38705 antibody; Met proto-oncogene, isoform CRA_c antibody; cDNA FLJ59332, highly similar to Hepatocyte growth factor receptor antibody; Hepatocyte growth factor receptor antibody
  • Immunogen
  • Isotype
    Mouse IgG1
  • Preparation
    This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human c-Met (rh c-Met; NP_000236; Met 1-Thr 932). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
  • Clonality
    Monoclonal
  • Formulation
    0.2 μm filtered solution in PBS with 5% trehalose
  • Storage instructions
    This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
    Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
  • Applications

    ELISA: 0.5-1 μg/mL

    This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect Human c-Met. The detection limit for Human c-Met is 0.078 ng/well.

  • Validations
  • Background
    Hepatocyte growth factor receptor (HGFR), also known as c-Met or mesenchymal-epithelial transition factor (MET), is a receptor tyrosine kinase (RTK) that has been shown to be overexpressed and/or mutated in a variety of malignancies. HGFR protein is produced as a single-chain precursor, and HGF is the only known ligand. Normal HGF/HGFR signaling is essential for embryonic development, tissue repair or wound healing, whereas aberrantly active HGFR has been strongly implicated in tumorigenesis, particularly in the development of invasive and metastatic phenotypes. HGFR protein is a multifaceted regulator of growth, motility, and invasion, and is normally expressed by cells of epithelial origin. Preclinical studies suggest that targeting aberrant HGFR signaling could be an attractive therapy in cancer.
  • References
    • McGill GG, et al. (2006) c-Met expression is regulated by Mitf in the melanocyte lineage. J Biol Chem. 281(15): 10365-73.
    • Garcia S, et al. (2007) c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays. British journal of cancer. 96(2): 329-35.
    • Socoteanu MP, et al. (2008) c-Met targeted therapy of cholangiocarcinoma. World J Gastroenterol. 14(19): 2990-4.
    • Kong DS, et al. (2009) Prognostic significance of c-Met expression in glioblastomas. Cancer. 115(1): 140-8.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"